Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $71
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Vik Chopra maintains an Equal-Weight rating on Conmed (NYSE:CNMD) but lowers the price target from $77 to $71.
August 01, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo analyst Vik Chopra maintains an Equal-Weight rating on Conmed but lowers the price target from $77 to $71.
The lowered price target from $77 to $71 by Wells Fargo suggests a less optimistic outlook for Conmed's stock performance, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100